Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Lactobacillus acidophilus L-92 and Improved Atopic Dermatitis Severity

Research synthesisModerate evidenceModerate effect4 studies · 4 beneficial · 0 neutral · 0 harmful

Across 4 studies, all reported beneficial moderate-sized effects of Lactobacillus acidophilus L-92 on improving atopic dermatitis severity. Three of the 4 studies found statistically significant improvements, with effects typically moderate in magnitude. The most-studied population includes young children with atopic dermatitis and food allergy, as well as adult patients, with doses including 20 mg L-92/day or heat-killed dried preparations, though study durations were not consistently reported.

  • Effective dose range: 20 mg L-92/day or heat-killed dried L-92 daily
  • Studied populations: Young children with atopic dermatitis and diagnosed or suspected food allergy; adult atopic dermatitis patients

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 4 studies) — conclusions should be considered preliminary. Study durations were not consistently reported, making it difficult to estimate how long supplementation is needed for benefit.

Generated Jul 11, 2026
Doses used in studies
  • CFU/day: 1 (median 1, IQR 11) 1 study
  • mg/day: 20 (median 20, IQR 2020) 1 study
Safety in these studies
4 of 4 papers
Back to top